Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors

Background Recombinant human granulocyte–colony‐stimulating factor (G‐CSF) is used to mobilize hematopoietic stem cells for both autologous and allogeneic hematopoietic stem cell transplantation. The recombinant products clinically available are lenograstim and filgrastim, which differ from a biolog...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2013-12, Vol.53 (12), p.3240-3242
Main Authors: Pérez-López, Olga, Martín-Sánchez, Jesús, Parody-Porras, Rocío, Espigado-Tocino, Ildefonso, Noguerol, Pilar, Carmona-González, Magdalena, Pérez-Simón, José A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antigens, CD34 - metabolism
Biological and medical sciences
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Child
Female
Filgrastim
Granulocyte Colony-Stimulating Factor - pharmacology
Hematopoietic Stem Cell Mobilization - methods
Hematopoietic Stem Cell Transplantation - methods
Humans
Male
Medical sciences
Middle Aged
Recombinant Proteins - pharmacology
Retrospective Studies
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Recombinant human granulocyte–colony‐stimulating factor (G‐CSF) is used to mobilize hematopoietic stem cells for both autologous and allogeneic hematopoietic stem cell transplantation. The recombinant products clinically available are lenograstim and filgrastim, which differ from a biologic point of view as well as from their economical impact. In this regard, some studies have shown different in vitro activities although clinical studies comparing both drugs in the allogeneic transplant setting are scanty. Study Design and Methods In the current study we compare the efficacy of lenograstim and filgrastim in terms of number of circulating CD34+ cells/μL during the fifth day of G‐CSF administration, the number of days of apheresis required to obtain the target cell dose, the median of CD34+ cells collected on the first day of apheresis, or the median number of total CD34+ cells collected at the end of the procedure, in a series of 146 healthy donors undergoing hematopoietic stem cell mobilization for allogeneic transplantation. Results We observed that, using a comparable dose for the two products, no significant differences were observed between the two groups. Conclusion In conclusion, the current retrospective study shows that lenograstim and filgrastim are similar in terms of efficacy for the mobilization of hematopoietic stem cells in healthy donors.
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.12157